Skin-directed electrochemotherapy: A prospective multi-institutional study on 394 patients with superficial tumors.
L Campana(University of Padua), Carlo Riccardo Rossi(University of Padua), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Gianni Gerlini(Tumour Institute of Tuscany), Gian Luca De Salvo(Istituto Oncologico Veneto), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), A Bonadies(San Gallicano Hospital), Michele Guida(Istituto Tumori Bari), Pietro Quaglino(Department of Medical Sciences), Ermenegildo Cubicciotti(Ospedale Antonio Cardarelli), Massimo Framarini(Ospedale G.B. Morgagni - L.Pierantoni), Federica Marenco(University Dermatology), Angela De Paoli, Roberta Rotunno(Sapienza University of Rome), P. Curatolo(Sapienza University of Rome)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k